Clinical trials: Neoplasm, Gastrointestinal
Pancreatic Cancer
Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer
This is a study to test whether different doses of 90Y-hPAM4 are safe to give in combination with gemcitabine in patients with previously untreated pancreatic cancer.
- Trial name
- NCT00603863
- Testing
- IMMU-107 (hPAM4)
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Gilead Sciences
Biliary Tract Cancer (BTC)
Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers
The goal of this clinical trial is to etablish whether adding Mitazalimab to standard chemotherapy is more effective than standard chemotherapy alone in people with advanced bile duct cancer.
- Trial name
- CROCOBIL (NCT07437287)
- Testing
- mFOLFOX regimen, Mitazalimab
- Where
- 22 sites in France
- Volunteers
- 160 people
- Sponsor
- UNICANCER
Pancreatic Pseudocyst
Laparoscopic Cystogastrostomy Versus Endoscopic Cystogastrostomy
This study is a randomized controlled trial comparing Laparoscopic and endoscopic drainage for pseudocyst of the pancreas secondary to acute pancreatitis.
- Trial name
- NCT02041793
- Testing
- Laparoscopic cystogastrostomy, Endoscopic cystogastrostomy
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences
Colonic Neoplasms
Enzastaurin for Patients With Metastatic Colorectal Cancer
Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer
- Trial name
- NCT00192114
- Testing
- Enzastaurin HCl
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Rectal Cancer, Surgery
Transanal Versus Laparoscopic Total Mesorectal Excision For Rectal Cancer
Total mesorectal excision (TME) has been prevailingly accepted as a crucial surgical intervention within the latest oncological therapeutic regime for mid-low rectal cancer.
- Trial name
- TLTME (NCT03359616)
- Testing
- Transanally curable surgical resection, Laparoscopic total mesorectal excision
- Volunteers
- 258 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Colorectal Cancer, Colorectal Cancer Metastatic
Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Microsatellite instability or mismatch repair deficiency occurs in 20% of CRC, and is predominantly found in non-metastatic tumors.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, MSI-H Colorectal Cancer, dMMR Colorectal Cancer
- Trial name
- BLOOMSI (NCT06414304)
- Where
- 2 sites in Russia
- Volunteers
- 30 people
- Sponsor
- OncoAtlas LLC
Ovarian Neoplasms, Colorectal Neoplasms
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Doctors will take some tissue from the tissue removed during surgery in order to study how the blood vessels of the tumor respond to radiation therapy.
- Conditions
- Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer
- Trial name
- NCT00132704
- Testing
- Ionizing radiation (IR) therapy, Ionizing radiation (IR)
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Oligometastatic Disease
Prediction of True Oligo-metastatic Disease.
In recent years, the scientific community has recognized the need to differentiate between poly- and oligo-metastatic disease (OMD) in oncology due to their distinct clinical and biological behavior.
- Trial name
- PREDICTION (NCT05806151)
- Testing
- Genetic and immunologic assessments
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute, Naples
Colorectal Cancer, Metabolic Disease
Impact of Environmental Factors and Metabolomics on Colorectal Cancer.
Colorectal cancer is one of the malignant tumours with high morbidity and mortality worldwide, posing a serious threat to human health.
- Trial name
- NCT06643429
- Testing
- colorectal cancer, colorectal neoplasm
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Dong Peng
Colo-rectal Cancer
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal…
- Trial name
- NCT06011772
- Testing
- Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Leucovorin, Oxaliplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Neoplasms, Endometrial Neoplasms
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06400472
- Testing
- Sofe-M, bevacizumab, carboplatin
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 575 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
ColoRectal Cancer Screening for Southern California Community Health Centers
Colorectal cancer (CRC) screening can reduce cancer deaths. However, screening and abnormal test follow-up rates are low among underserved populations.
- Trial name
- NCT04941300
- Testing
- Mailed FIT Outreach, Standardized navigation
- Where
- United States
- Volunteers
- 55,999 people
- Sponsor
- University of California, San Diego
Colorectal Cancer (CRC)
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Colorectal Cancer (CRC)
- Trial name
- NCT07106892
- Testing
- HLX43 Dose 1;, HLX43 Dose 2;, HLX43 Dose 3;
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Henlius Biotech
Hepatitis, Liver Cirrhosis
Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease
BACKGROUND The insulin-like growth factor system (IGFs) plays an important role in cell growth and differentiation. Nevertheless, the roles played by insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding…
- Conditions
- Hepatitis, Liver Cirrhosis, Hepatocellular Carcinoma
- Trial name
- NCT00679692
- Where
- Taiwan
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Zenker Diverticulum, Polyp of Colon
Advanced Endo-therapeutic Procedure : Registry-based Observational Study
Advanced therapeutic endoscopy procedures are of increasing importance to provide minimal invasive treatment for GI diseases. The Centre Hospitalier de l'Université de Montréal as tertiary university center is dedicated to…
- Conditions
- Zenker Diverticulum, Polyp of Colon, Colo-rectal Cancer
- Trial name
- AE Registry (NCT04117100)
- Testing
- Polypectomy or myotomy
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Colorectal Cancer
Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery
The goal of this study is to compare the effects of exercise with the effects of relaxation training on physical function (how well participants perform normal daily activities) and symptoms related to your cancer diagnosis (such…
- Trial name
- NCT00985400
- Testing
- Exercise Program, Telephone-based intervention, Counseling intervention
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- M.D. Anderson Cancer Center
Colonic Neoplasms, Neoplasms, Colon
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/…
- Trial name
- NCT05855200
- Testing
- Dostarlimab, CAPEOX, FOLFOX
- Where
- 266 sites in United States, Argentina and 26 more
- Volunteers
- 892 people
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma
Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.
- Trial name
- NCT01266707
- Testing
- antiangiogenic paptide vaccine
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Fukushima Medical University
Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
- Conditions
- Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer
- Trial name
- PACT (NCT02791334)
- Testing
- LY3300054, Ramucirumab, Abemaciclib
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 164 people
- Sponsor
- Eli Lilly and Company
Unresectable Hepatocellular Carcinoma
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research.
- Trial name
- NCT05135364
- Testing
- Camrelizumab, HAIC, TKI
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Yue Han
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.